Company research
Cocrystal Pharma, Inc.
CIK 1412486Updated Nov 9, 2026
SecurityCOCP · NASDAQ · equity
Name history
BIOZONE PHARMACEUTICALS, INC. · through Mar 25, 2014International Surf Resorts, Inc. · through Mar 4, 2011
COCP price & chart
Loading TradingView…
NASDAQ:COCP on TradingView ↗About the company
Cocrystal is a clinical-stage biotechnology company seeking to discover and develop novel antiviral therapeutics as treatments for serious and/or chronic viral diseases. We employ unique structure-based technologies and Nobel Prize winning expertise to create antiviral drugs. These technologies are designed to efficiently deliver small molecule therapeutics that are safe, effective, and convenient to administer. We have identified promising discovery, preclinical and clinical stage antiviral compounds for unmet medical needs caused by coronavirus, influenza virus and norovirus.
In the news
Cocrystal Pharma Appoints James Sapirstein, Biopharma Industry Leader with Extensive Antiviral Development Experience, as Chief Executive Officer ↗
Seeking Alpha
Cocrystal Pharma GAAP EPS of -$0.78 beats by $0.02 ↗
Recent filings
SCHEDULE 13D/A - filed by OPKO HEALTH, INC. regarding Cocrystal Pharma, Inc.
Regulation FD Disclosure
Items 7.01, 9.01
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02, 9.01
Regulation FD Disclosure
Items 7.01, 9.01
10-Q filing
Show 5 more recent filings
4 filing
4 filing
Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities · Regulation FD Disclosure
Items 1.01, 3.02, 7.01, 9.01
Submission of Matters to a Vote of Security Holders
Items 5.07
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 10,446,000Source | 16,233,000Source | 4,649,000Source | 8,505,000Source | 21,573,000Source | 7,426,000Source | 10,659,000Source | 26,546,000Source | 9,712,000Source | 13,456,000Source | 31,259,000Source | 40,840,000Source |
| Property, Plant and Equipment, NetUSD | 106,000Source | 181,000Source | 69,000Source | 107,000Source | 211,000Source | 81,000Source | 127,000Source | 244,000Source | 93,000Source | 153,000Source | 271,000Source | 342,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | — | — | — | — | 18,143,000Source | — | — | 21,842,000Source | 7,025,000Source | 9,860,000Source | 26,353,000Source | 37,219,000Source |
| Assets, CurrentUSD | 8,782,000Source | 14,256,000Source | 3,236,000Source | 6,765,000Source | 19,660,000Source | 5,939,000Source | 8,826,000Source | 24,492,000Source | 8,134,000Source | 11,580,000Source | 29,091,000Source | 40,178,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 465,000Source | 509,000Source | 256,000Source | 282,000Source | 365,000Source | 418,000Source | 385,000Source | 1,572,000Source | 328,000Source | 430,000Source | 1,773,000Source | 2,243,000Source |
| Operating Lease, Right-of-Use AssetUSD | 1,468,000Source | 1,767,000Source | 1,230,000Source | 1,545,000Source | 1,673,000Source | 1,311,000Source | 1,620,000Source | 1,764,000Source | 1,390,000Source | 1,694,000Source | 1,851,000Source | 274,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 2,777,000Source | 3,530,000Source | 3,605,000Source | 3,172,000Source | 4,183,000Source | 3,310,000Source | 3,355,000Source | 3,961,000Source | 3,381,000Source | 3,933,000Source | 4,875,000Source | 1,273,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 13,000Source | 10,000Source | 13,000Source | 10,000Source | 10,000Source | 13,000Source | 10,000Source | 10,000Source | 13,000Source | 10,000Source | 10,000Source | 8,000Source |
| Retained Earnings (Accumulated Deficit)USD | -339,823,000Source | -330,152,000Source | -347,712,000Source | -337,774,000Source | -325,213,000Source | -344,548,000Source | -335,719,000Source | -319,870,000Source | -342,249,000Source | -333,418,000Source | -315,914,000Source | -297,930,000Source |
| Stockholders' Equity Attributable to ParentUSD | 7,669,000Source | 12,703,000Source | 1,044,000Source | 5,333,000Source | 17,390,000Source | 4,116,000Source | 7,304,000Source | 22,585,000Source | 6,331,000Source | 9,523,000Source | 26,384,000Source | 39,567,000Source |
| Additional Paid in Capital, Common StockUSD | 347,479,000Source | 342,845,000Source | 348,743,000Source | 343,097,000Source | 342,593,000Source | 348,651,000Source | 343,013,000Source | 342,445,000Source | 348,567,000Source | 342,931,000Source | 342,288,000Source | 337,489,000Source |
| Liabilities and EquityUSD | 10,446,000Source | 16,233,000Source | 4,649,000Source | 8,505,000Source | 21,573,000Source | 7,426,000Source | 10,659,000Source | 26,546,000Source | 9,712,000Source | 13,456,000Source | 31,259,000Source | 40,840,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 1,520,000Source | 1,948,000Source | 2,616,000Source | 1,831,000Source | 2,654,000Source | 2,229,000Source | 1,931,000Source | 2,379,000Source | 2,210,000Source | 2,428,000Source | 3,262,000Source | 1,216,000Source |
| Operating Lease, Liability, CurrentUSD | 326,000Source | 293,000Source | 352,000Source | 317,000Source | 251,000Source | 343,000Source | 309,000Source | 240,000Source | 334,000Source | 301,000Source | 240,000Source | 233,000Source |
| Accounts Payable, CurrentUSD | 745,000Source | 859,000Source | 1,892,000Source | 856,000Source | 1,743,000Source | 1,371,000Source | 808,000Source | 1,234,000Source | 890,000Source | 1,542,000Source | 1,222,000Source | 614,000Source |
| Operating Lease, Liability, NoncurrentUSD | 1,257,000Source | 1,582,000Source | 989,000Source | 1,341,000Source | 1,529,000Source | 1,081,000Source | 1,424,000Source | 1,582,000Source | 1,171,000Source | 1,505,000Source | 1,613,000Source | 57,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation and amortization | — | — | — | — | — | — | —Source | —Source | —Source | —Source | —Source | —Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 84,000Source | 82,000Source | 270,000Source | 643,000Source | 801,000Source | 855,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -2,340,000Source | -2,939,000Source | -8,192,000Source | -16,485,000Source | -14,666,000Source | -21,435,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | — | — | -12,000Source | -8,000Source | -118,000Source | -74,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | — | 12,000Source | 8,000Source | 118,000Source | 74,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | — | — | 5,369,000Source | — | 3,993,000Source | -27,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -2,340,000Source | -2,939,000Source | -2,835,000Source | -16,493,000Source | -10,791,000Source | -21,536,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 48,000Source | 252,000Source | — | — | 84,000Source | 82,000Source | 270,000Source | 643,000Source | 801,000Source | 855,000Source |
| Derivative, Gain (Loss) on Derivative, NetUSD | — | — | — | — | — | — | — | — | — | — | — | 12,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | 18,000Source | -8,000Source | 10,000Source | 25,000Source | 35,000Source | 3,000Source | 54,000Source | -163,000Source | -65,000Source | -18,000Source |
| General and Administrative ExpenseUSD | — | — | 1,135,000Source | 1,800,000Source | 1,147,000Source | 986,000Source | 1,210,000Source | 981,000Source | 3,964,000Source | 5,341,000Source | 5,990,000Source | 5,745,000Source |
| InterestExpenseNonoperatingUSD | — | — | -22,000Source | -111,000Source | -10,000Source | -28,000Source | -22,000Source | -37,000Source | -134,000Source | -537,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -2,049,000Source | -4,939,000Source | -3,164,000Source | -2,055,000Source | -2,299,000Source | -2,301,000Source | -8,831,000Source | -17,504,000Source | -17,984,000Source | -38,837,000Source |
| Nonoperating Income (Expense)USD | — | — | 40,000Source | 103,000Source | 20,000Source | 53,000Source | 57,000Source | 40,000Source | 188,000Source | 374,000Source | 575,000Source | -8,000Source |
| Operating Costs and ExpensesUSD | — | — | — | — | — | — | — | — | — | 2,200,000Source | 3,050,000Source | — |
| Operating ExpensesUSD | — | — | 2,089,000Source | 5,042,000Source | 3,289,000Source | 2,108,000Source | 2,581,000Source | 2,341,000Source | 9,019,000Source | 17,878,000Source | 18,559,000Source | 38,829,000Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | 102,000Source | 103,000Source | 578,000Source | 393,000Source | — | 203,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | 154,000Source | — | 4,000,000Source | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | — | — | — | —Source | — | — | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — | — | — | — | — | — | — |
| Income Tax Expense (Benefit) | — | — | — | — | — | — | —Source | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -2,089,000Source | -5,042,000Source | -3,184,000Source | -2,108,000Source | -2,356,000Source | -2,341,000Source | -9,019,000Source | -17,878,000Source | -18,559,000Source | -38,829,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | -8,831,000Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -2,049,000Source | -4,939,000Source | -3,164,000Source | -2,055,000Source | -2,299,000Source | -2,301,000Source | -8,831,000Source | -17,504,000Source | -17,984,000Source | -38,837,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.19Source | -0.49Source | -0.23Source | -0.2Source | -0.17Source | -0.23Source | -0.78Source | -1.72Source | -1.87Source | -4.77Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.19Source | -0.49Source | -0.23Source | -0.2Source | -0.17Source | -0.23Source | -0.78Source | -1.72Source | -1.87Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 10,991,000Source | 10,174,000Source | 13,788,000Source | 10,174,000Source | 13,786,000Source | 10,174,000Source | 11,290,000Source | 10,174,000Source | 9,651,000Source | 8,143,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 10,991,000Source | 10,174,000Source | 13,788,000Source | 10,174,000Source | 13,786,000Source | 10,174,000Source | 11,290,000Source | 10,174,000Source | 9,651,000Source | — |
| Interest Expense (non-operating)USD | — | — | -22,000Source | -111,000Source | -10,000Source | -28,000Source | -22,000Source | -37,000Source | -134,000Source | -537,000Source | — | — |
| Additional Financial Items | ||||||||||||
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | — | — | — | 12,000Source | 25,000Source | 72,000Source | 126,000Source | 189,000Source | 185,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | 18,000Source | -8,000Source | 10,000Source | 25,000Source | 35,000Source | 3,000Source | 54,000Source | -163,000Source | -65,000Source | -18,000Source |
| General and Administrative ExpenseUSD | — | — | 1,135,000Source | 1,800,000Source | 1,147,000Source | 986,000Source | 1,210,000Source | 981,000Source | 3,964,000Source | 5,341,000Source | 5,990,000Source | 5,745,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -7,868,000Source | — | — | — |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | -640,000Source | 2,000Source |
| Nonoperating Income (Expense)USD | — | — | 40,000Source | 103,000Source | 20,000Source | 53,000Source | 57,000Source | 40,000Source | 188,000Source | 374,000Source | 575,000Source | -8,000Source |
| Operating Costs and ExpensesUSD | — | — | — | — | — | — | — | — | — | 2,200,000Source | 3,050,000Source | — |
| Operating ExpensesUSD | — | — | 2,089,000Source | 5,042,000Source | 3,289,000Source | 2,108,000Source | 2,581,000Source | 2,341,000Source | 9,019,000Source | 17,878,000Source | 18,559,000Source | 38,829,000Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | 102,000Source | 103,000Source | 578,000Source | 393,000Source | — | 203,000Source |
| Research and Development ExpenseUSD | — | — | 954,000Source | 3,242,000Source | 2,142,000Source | 1,122,000Source | 1,371,000Source | 1,360,000Source | 5,055,000Source | 12,537,000Source | 15,169,000Source | 12,392,000Source |
| Total Revenue | — | — | — | — | —Source | — | —Source | — | — | — | — | — |
| Income Tax Expense (Benefit) | — | — | — | — | — | — | —Source | — | — | — | — | — |
| Other Income | — | — | — | — | — | — | —Source | — | — | — | — | — |
Offerings
Registration 333-295279
Registration 333-290407
Filing attachments
ex99-1.htm · 8-K · 2026-09-09
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Cocrystal Pharma Announces Last Subject Dosed in Phase 1b Human Challenge Study Evaluating CDI-988 for Norovirus Prevention and Treatment No serious adverse events reported to date Preliminary efficacy results expected in late 2026 or early 2027 MIAMI, Fla. And BOTHELL, Wash., September 09, 2026 - Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a biotechnology company developing novel therapeutics to meet the growing global …
Read attachment ↗ex99-1.htm · 8-K · 2026-08-17
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Cocrystal Pharma Appoints Carol Brosgart, MD to its Board of Directors BOTHELL, Wash., August 17, 2026 - Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biotechnology company developing novel therapeutics to meet the growing global need for effective, safe antiviral treatments, today announced the appointment of Carol Brosgart, MD to its Board of Directors, effective August 12, 2026. Dr. Brosgart brings severa…
Read attachment ↗ex99-1.htm · 8-K · 2026-08-03
EX-99.1 3 ex99-1.htm EX-99.1 Exhibit 99.1 Cocrystal Pharma Announces $5 Million Private Placement with OPKO Health Longtime investor OPKO Health increases its position as Cocrystal advances toward norovirus Phase 1b data in late 2026 BOTHELL, Wash., August 3, 2026 (GLOBE NEWSWIRE) - Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a biotechnology company developing novel antiviral therapeutics, today announced a $5 million investment from OPKO Health, Inc. (Nasdaq: OP…
Read attachment ↗ex99-1.htm · 8-K · 2026-06-03
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Cocrystal Pharma Appoints James Sapirstein, Biopharma Industry Leader with Extensive Antiviral Development Experience, as Chief Executive Officer BOTHELL, Wash., June 3, 2026 - Cocrystal Pharma Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biotechnology company developing novel therapeutics to meet the growing need for effective, safe antiviral treatments, has appointed James Sapirstein Chief Executive Officer, effective imme…
Read attachment ↗ex99-1.htm · 8-K · 2026-05-26
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Cocrystal Pharma Announces Discovery of Pan-Viral Inhibitors Targeting Hantavirus, Bunyavirus and Influenza Novel, potent pan-viral inhibitors targeting the viral replication complex are under development for the treatment of hantavirus, bunyavirus and influenza Hantavirus and bunyavirus infections represent significant unmet medical needs, contribute to ongoing global outbreaks and have no approved treatments or vaccines BOTHELL, Was…
Read attachment ↗ex99-1.htm · 8-K · 2026-04-30
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Cocrystal Pharma Presentation at ICAR 2026 Highlights Mechanism of Action and Clinical Advancement of CDI-988 for the Prevention and Treatment of Norovirus Infection Ongoing Phase 1b human challenge study with oral, direct-acting protease inhibitor is designed to demonstrate proof-of-concept as a preventive and a treatment Fully enrolled first cohort is assessing the infectivity of the human challenge inoculum There are no approved tr…
Read attachment ↗